1. Cha E, Wallin J, Kowanetz M. PD-L1 inhibition with MPDL3280A for solid tumors. In: Semin Oncol. WB Saunders; 2015:484–87. https://doi.org/10.1053/j.seminoncol.2015.02.002.
2. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens RA, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32:8024. https://doi.org/10.1200/jco.2014.32.15_suppl.8024.
3. Genentech. FDA approves Genentech’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer. May 18, 2020. Available from: https://bit.ly/2ZfNjHK
4. US FDA. FDA approves durvalumab for extensive-stage small cell lung cancer. March 30, 2020. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer
5. US FDA. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%). April 11, 2019. Available from: https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1